Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04381117 · ClinicalTrials.gov registry record
Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)
A clinical trial of Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- 7
- Enrollment target
- 4
- Study locations
NCT04381117 is a study of Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 7 participants, below the 224-participant average among 3 other Edematous Fibrosclerotic Panniculopathy trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04381117, a study of Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the long-term safety and duration of efficacy of CCH in the treatment of women with cellulite. This study will be a single day evaluation, approximately 48 months after the first dose of study drug was received in the EN3835-201.
Conditions Studied
Interventions
- DRUG Previously Treated with EN3835
Study Locations (4)
Florida
- Clinical Trial Site #4 - Clearwater
- Endo Clinical Trial Site #2 - Coral Gables
Missouri
- Endo Clinical Trial Site #3 - Washington
New York
- Endo Clinical Trial Site #1 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-05-06 |
| Est. Completion | 2020-06-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04381117
The ClinicalTrials.gov registry entry for NCT04381117 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 224-participant average among 3 other Edematous Fibrosclerotic Panniculopathy trials with a reported enrollment target (97% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Edematous Fibrosclerotic Panniculopathy appearing as the primary indexed condition, and to 1 intervention - of which Previously Treated with EN3835 is the first listed.
NCT04381117 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT04381117 about?
NCT04381117 is a clinical study titled "Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)". This study will evaluate the long-term safety and duration of efficacy of CCH in the treatment of women with cellulite. This study will be a single day evaluation, approximately 48 months after the first dose of study drug was received in the EN3835-201.
What is the current status of trial NCT04381117?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2020-05-06. Estimated completion is 2020-06-22.
What conditions does trial NCT04381117 study?
This clinical trial studies the following conditions: Edematous Fibrosclerotic Panniculopathy.
What interventions are being tested in trial NCT04381117?
The interventions under investigation include: Previously Treated with EN3835 (DRUG).
Who is sponsoring clinical trial NCT04381117?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04381117 being conducted?
This trial has 4 study locations across Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Edematous Fibrosclerotic Panniculopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
COMPLETED · Phase 2
-
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
COMPLETED · Phase 1
-
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.